Abstract
Background:
Adiponectin is secreted by adipocytes and is inversely associated with obesity. Given the association between low body mass index (BMI) and higher mortality risk after community-acquired pneumonia (CAP), we hypothesized that high adiponectin levels are associated with a higher risk of adverse clinical outcomes in patients with CAP.
Methods:
In a prospective cohort study of 502 patients hospitalized with CAP, adiponectin was measured in serum at admission. The associations between adiponectin and clinical outcomes were estimated with logistic regression analyses adjusted for age, sex, and measures of obesity (BMI, waist circumference or body fat percentage).
Results:
Adiponectin was associated with higher 90-day mortality for each 1 μg/mL increase [OR 1.02, 95% CI (1.00, 1.04), p = 0.048] independent of age and sex. Likewise, adiponectin was associated with a higher risk of 90-day readmission for each 1 μg/mL increase [OR 1.02, 95% CI (1.01, 1.04), p = 0.007] independent of age and sex. The association between adiponectin and 90-day mortality disappeared, while the association with 90-day readmission remained after adjusting for adiposity.
Conclusion:
Adiponectin was positively associated with mortality and readmission. The association with mortality depended on low body fat, whereas the association with readmission risk was independent of obesity.
1 Introduction
Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide, with 90-day mortality rates up to 22% (1–4). Obese and underweight individuals have an increased risk of acquiring CAP (5, 6), whereas underweight patients with CAP have a higher mortality risk than normal-weight, overweight, and obese patients (7).
Individuals with obesity have increased fat and muscle mass, whereas underweight individuals have reduced fat and muscle mass (8). Adipose tissue secretes several adipokines, including adiponectin, with metabolic and immunological functions (9–11). Adiponectin is almost exclusively secreted by adipocytes (12). Mice studies have shown that adiponectin exerts several beneficial effects, including anti-inflammatory, anti-atherogenic, anti-apoptotic, and insulin-sensitizing effects (11). In humans, increasing age and female sex are associated with higher adiponectin levels, while obesity, type 2 diabetes mellitus and insulin resistance are associated with lower adiponectin levels (9). In addition, progressive weight loss increases adiponectin levels after bariatric surgery, caloric restriction (13, 14) or cachexia associated with chronic diseases (15–17).
Given the beneficial effects shown in mice studies, high adiponectin levels have been paradoxically associated with increased mortality from chronic diseases, including cardiovascular diseases, chronic obstructive pulmonary disease (COPD), cancer, and diabetes mellitus in epidemiological studies (18). However, the role of adiponectin in acute infections is incompletely understood with conflicting data as both low (19) and high (20, 21) adiponectin levels have been associated with higher sepsis-related mortality.
Given the inverse association between adiponectin and body mass index (BMI) (9) and the association between low BMI and increased mortality risk after CAP (7), we hypothesized that high levels of adiponectin are associated with an increased risk of adverse clinical outcomes in patients hospitalized with CAP. Therefore, this study aimed to assess the association between serum adiponectin levels and adverse clinical outcomes and predictors of adiponectin levels at admission in hospitalized patients with CAP.
2 Methods
2.1 Reporting
The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting observational cohort studies were followed when reporting this study (22).
2.2 Design and setting
This study used the Surviving Pneumonia research platform. Surviving pneumonia is an observational, prospective cohort study including hospitalized patients with CAP at Copenhagen University Hospital - North Zealand, Denmark. Patients were enrolled at the Emergency Department and medical wards between January 2019 and April 2021 and followed for 90 days after admission. The exposure was adiponectin measured at baseline.
2.3 Participants
In Surviving Pneumonia, all patients hospitalized with a suspected lower respiratory tract infection were screened for eligibility. The eligibility criteria were age ≥ 18 years, new infiltrate on chest x-ray or chest computed tomography scan and at least one symptom or clinical sign consistent with pneumonia, e.g., cough, sputum production, fever (≥38.0°C), hypothermia (<35.0°C), chest pain, breathlessness, and abnormal chest auscultation. The exclusion criterion for the present study was a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients were enrolled within 24 h of admission.
2.4 Ethical considerations
The study was approved by the Scientific Ethics Committee at the Capital Region of Denmark (H-18024256), registered on ClinicalTrials.gov (NCT03795662), and conducted in accordance with the Declaration of Helsinki (23). Oral and written informed consent was obtained from all patients before enrolment.
2.5 Data collection and variables
Data were collected prospectively with standardized forms and entered into a REDCap database by a few experienced nurses to reduce information bias (24). Information about demography, past medical history, comorbidities, radiology reports, vital signs at admission, blood test results, microbiological test results, and clinical outcomes were collected during a structured interview at study enrolment and from the electronic medical record during the follow-up period. The comorbidity burden was assessed with the Charlson comorbidity index (CCI) (2). Low, medium and high CCI was defined as an index score of 0, 1–2, and ≥3, respectively (2). CAP severity was assessed with the CURB-65 score based on level of confusion, respiratory rate, systolic or diastolic blood pressure and age (25). Clinical stability was defined according to the modified Halm’s criteria when temperature ≤ 37.2°C, heart rate ≤ 100 beats/min, respiratory rate ≤ 24 breaths/min, systolic blood pressure ≥ 90 mm Hg and oxygen saturation ≥ 90% without supplemental oxygen therapy (or habitual oxygen) and quantified in hours since admission (26).
2.6 Anthropometric and body composition data
Anthropometric measurements and body composition estimation were performed 24 h after study enrolment. BMI was calculated from self-reported height in meters and weight measured to the nearest 0.1 kg on an electric scale (Seca, Hamburg, Germany). Waist circumference was measured midway between the lowest portion of the rib cage and the uppermost portion of the iliac crest at the umbilical level. Underweight, normal weight, overweight and obesity were defined as BMI < 18.5, 18.5–24.9, 25.0–29.9 and >30 kg/m2, respectively. Body fat percentage (%) was estimated with bioimpedance analysis (BioScan touch i8 STD, Maltron International, United Kingdom) using multi-frequency (5, 50, 100, and 200 kHz) hand-to-foot measurements of resistance and reactance with the patient in a supine position.
2.7 Adiponectin and routine blood samples
Blood samples were collected in serum tubes and centrifuged at 3,000 x g for 15 min at 4°C. The supernatant was stored at −80°C. Serum adiponectin was measured with a commercially available immunoassay (R-PLEX® Human Adiponectin Antibody Set, Meso Scale Diagnostics, Rockville, Maryland, United States) on an electrochemiluminescent platform (Meso Scale Diagnostics, Rockville, Maryland, United States) according to the manufacturer’s instructions. All samples were run in duplicate. The inter-and intra-assay coefficient of variation was <8%. Standard blood tests such as c-reactive protein (CRP) and plasma glucose were performed daily at the attending physician’s discretion.
2.8 Outcome measures and confounders
The primary outcome was 90-day mortality. The secondary outcomes were associations of adiponectin with baseline characteristics, in-hospital mortality, the need for non-invasive respiratory support (high flow oxygen therapy, continuous positive airway pressure therapy), intensive care unit (ICU) transferral, time to clinical stability, length of stay (LOS), and 90-day readmission. Age, sex, and adiposity measures were included as confounders in all analyses, with adiponectin as a predictor according to the directed acyclic graphs of the expected causal relationships (Supplementary Figure 1).
2.9 Statistical analyses
The continuous variables were skewed and reported as medians [interquartile range (IQR)]. Categorical variables were reported as counts and percentages. As BMI influences adiponectin levels (27), baseline characteristics of patients with and without a BMI measurement were compared. Comparisons of 2 independent samples were performed with Mann–Whitney U tests. Kruskal–Walli’s test was used for more than two independent samples, followed by Dunns’s post hoc test for multiple comparisons. Differences in categorical variables were estimated with the chi-squared test.
The study participants were divided into four groups based on the sex-stratified quartile distribution of baseline adiponectin because adiponectin levels are higher in females than males (9). Cumulative mortality during the follow-up period across the adiponectin quartiles was assessed with Kaplan–Meier curves and log-rank tests.
Associations between baseline characteristics and adiponectin were modeled with univariate and multivariate linear regression adjusted for age, sex, BMI, select comorbidities (diabetes mellitus, COPD, ischemic heart disease, heart failure, chronic kidney disease, cancer, rheumatic disease), CURB-65 score, and admission CRP level.
The association of continuous outcome variables with adiponectin was estimated with linear regression. Continuous outcome variables, including adiponectin, were skewed and log-transformed to satisfy linear regression model assumptions. The reported exponentiated β-coefficients with 95% CI represent the fold change. Logistic regression was used to estimate the association of categorical outcome variables with adiponectin and reported as odds ratios (OR) with 95% CI. The regression models for all outcomes except where adiponectin was the outcome variable were adjusted for age and sex (minimally adjusted models), followed by subsequent adjustments for BMI (fully adjusted models). Adiponectin was evaluated as a continuous variable and quartiles in these models.
Patients who died in-hospital were excluded from analyses where the outcome variable was 90-day readmission, LOS, or time clinical stability. In addition, patients with a do-not-resuscitate order or limitations on life-sustaining treatment were excluded from analyses where ICU admission was the outcome variable.
Complete case analysis was performed in case of missing independent variables in the regression analyses. Sensitivity analyses were performed by entering waist circumference or body fat % in the regression models instead of BMI as more precise measures of adiposity (8). BMI was the primary measure of adiposity because more patients had an available BMI measurement than waist circumference or fat percentage. The statistical comparisons were 2-sided, with p < 0.05 as the significance level. The statistical analyses were conducted with R software (R version 4.0.3).
3 Results
3.1 Patient characteristics
Among the 3,100 patients screened for eligibility, 502 fulfilled the inclusion criteria and were included (Figure 1). Patient characteristics are shown in Table 1. The median age was 74 years (IQR, 65–81), 50% were female, 6.2% were underweight, 58% were overweight or obese, and 80% had a CCI score ≥ 3. Furthermore, 38, 20, and 19% of the patients had been diagnosed with COPD, cancer, or diabetes, respectively. Patients with no BMI measurement (20%) were older and had higher CCI scores, disease severity, and mortality rate than those with a BMI (Table 2). Adiponectin levels were similar in patients with and without a BMI measurement [median 19 (IQR, 13–27) μg/mL vs. 22 (IQR, 13–30) μg/mL, p = 0.2].
Figure 1
Flow chart of patient enrolment. 2,433 were excluded because they did not fulfill all inclusion criteria. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 1
| Variable | Median (IQR) or n (%) |
|---|---|
| Demography | |
| Age, years | 74 (65–81) |
| Sex, female | 249 (50) |
| Anthropometry | |
| Body mass index (kg/m2)# | 26 (22–30) |
| Waist circumference (cm)# | 100 (90–110) |
| Body fat percentage# | 29 (23–38) |
| Comorbidities | |
| Diabetes | 94 (19) |
| COPD | 189 (38) |
| Ischemic heart disease | 48 (9.6) |
| Heart failure | 78 (16) |
| Chronic kidney disease | 15 (3.0) |
| Cancer | 97 (20) |
| Rheumatic disease | 30 (6.0) |
| Charlson comorbidity index | 5 (3–6) |
| Disease severity | |
| CURB-65 score | |
| Mild (0–1) | 269 (54) |
| Moderate (2) | 173 (34) |
| Severe (3–5) | 60 (12) |
| Baseline blood biomarkers | |
| Serum adiponectin (μg/ml) | 19 (13–28) |
| C-reactive protein (mg/l) | 106 (45–174) |
| Clinical outcomes | |
| Primary | |
| 90-day mortality | 76 (15) |
| Secondary | |
| In-hospital mortality | 32 (6.4) |
| ICU transferral | 16 (3.2) |
| Mechanical ventilation | 8 (1.6) |
| CPAP or high-flow oxygen therapy | 54 (11) |
| Length of stay (days) | 5 (4–9) |
| Time to clinical stability (hours) | 100 (50–175) |
| 90-day readmission | 168 (33) |
Baseline characteristics and clinical outcomes of 502 patients hospitalized with community-acquired pneumonia.
#Missing data: BMI 20%, body fat percentage 38%, waist circumference 41%. COPD, chronic obstructive pulmonary disease; CURB-65 score is based on 5 variables: confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg and age ≥65 years; CPAP, continuous positive airway pressure; hrs, hours; ICU, intensive care unit; IQR, interquartile range.
Table 2
| Characteristic | N | No BMI N = 102 |
BMI available N = 400 |
p-value1 |
|---|---|---|---|---|
| Demography | ||||
| Age, years | 502 | 78 (70, 85) | 73 (64, 80) | 0.003 |
| Sex, female | 502 | 46 (45%) | 203 (51%) | 0.3 |
| Comorbidities | ||||
| Charlson comorbidity index | 491 | 5 (4, 7) | 4 (3, 6) | 0.006 |
| Disease severity | ||||
| CURB-65 score | 502 | <0.001 | ||
| Mild (0–1) | 39 (38%) | 230 (57%) | ||
| Moderate (2) | 42 (41%) | 131 (33%) | ||
| Severe (3–5) | 21 (21%) | 39 (9.8%) | ||
| Clinical outcomes | ||||
| Primary | ||||
| Non-survivor | 502 | 23 (23%) | 53 (13%) | 0.019 |
| Secondary | ||||
| In-hospital mortality | 492 | 11 (11%) | 21 (5.3%) | 0.028 |
| ICU-admission | 502 | 6 (6.2%) | 20 (5.1%) | 0.6 |
| CPAP or high-flow O2 | 502 | 9 (8.8%) | 45 (11%) | 0.5 |
| Length of stay (days) | 502 | 5 (4, 8) | 5 (4, 9) | 0.3 |
| Time to clinical stability (hours) | 495 | 92 (41, 162) | 102 (53, 179) | 0.2 |
| 90-day readmission | 502 | 27 (26%) | 141 (35%) | 0.093 |
Patient characteristics and clinical outcomes according to the availability of a BMI measurement.
1Mann–Whitney U tests test; Pearson’s Chi-squared test. COPD, chronic obstructive pulmonary disease; CURB-65 score is based on 5 variables: confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg and age ≥65 years; CPAP, continuous positive airway pressure; hrs, hours; ICU, intensive care unit; IQR, interquartile range.
3.2 Association between adiponectin and baseline characteristics
Patients presenting with moderate or severe disease, according to the CURB-65 score, had higher adiponectin levels than patients with mild disease (Figure 2). In multivariate linear regression analyses, increasing age, female sex, having COPD, and rheumatic disease were associated with higher adiponectin levels, whereas increasing BMI, having diabetes mellitus, and higher admission CRP were associated with lower adiponectin levels (Table 3).
Figure 2
Boxplot of baseline serum adiponectin levels (μg/mL) stratified by CURB-65 score. The line within the box represents the median serum adiponectin levels, and each box represents the upper and lower quartiles. The jittered points around each boxplot represent the distribution of adiponectin. Statistical comparisons were made with Mann–Whitney U tests for two-group comparisons or Kruskal–Wallis tests in case of more than two independent samples, followed by Dunns’s post hoc test for multiple comparisons. p, p-value.
Table 3
| Univariate models | Multivariate model | |||||
|---|---|---|---|---|---|---|
| Predictors | β | 95% CI | p-value | β | 95% CI | p-value |
| Waist circumference (cm)a | 0.99 | 0.98–0.99 | <0.001 | |||
| Body fat %b | 0.99 | 0.99–1.00 | 0.03 | |||
| BMI (kg/m2)c | 0.97 | 0.96–0.98 | <0.001 | 0.98 | 0.97–0.99 | <0.001 |
| Age years | 1.01 | 1.01–1.02 | <0.001 | 1.01 | 1.00–1.01 | 0.001 |
| Sex (female) | 1.24 | 1.13–1.37 | <0.001 | 1.28 | 1.17–1.40 | <0.001 |
| Diabetes | 0.74 | 0.66–0.84 | <0.001 | 0.80 | 0.71–0.91 | 0.001 |
| COPD | 1.36 | 1.24–1.50 | <0.001 | 1.22 | 1.10–1.34 | <0.001 |
| Ischemic heart disease | 1.02 | 0.86–1.20 | 0.837 | 0.90 | 0.76–1.07 | 0.220 |
| Heart failure | 1.14 | 1.00–1.30 | 0.053 | 1.04 | 0.91–1.19 | 0.544 |
| Chronic kidney disease | 1.12 | 0.84–1.48 | 0.443 | 1.24 | 0.95–1.63 | 0.114 |
| Cancer | 1.13 | 1.00–1.28 | 0.044 | 1.02 | 0.90–1.15 | 0.757 |
| Rheumatic disease | 1.32 | 1.08–1.62 | 0.007 | 1.24 | 1.03–1.50 | 0.023 |
| CRP (50 mg/L increase) | 0.94 | 0.91–0.96 | <0.001 | 0.94 | 0.92–0.96 | <0.001 |
| CURB-65 score | 1.11 | 1.05–1.16 | <0.001 | 1.03 | 0.97–1.10 | 0.322 |
Linear regression analyses of the associations between baseline characteristics and adiponectin levels.
Data are from linear regression analyses with log-transformed adiponectin as the dependent variable. Data are reported as fold change in regression coefficient (β) after back transformation. BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; CURB-65 score is based on 5 variables: confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg and age ≥65 years.
aBased on 296 observations.
bBased on 311 observations.
cBased on 400 observations.
3.3 90-day mortality (primary endpoint)
Adiponectin levels were higher in non-survivors compared to survivors (Figure 3). The survival curves showed a decreasing survival probability with increasing adiponectin quartiles (p < 0.003) (Figure 4). The 90-day survival probability was 94% (95% CI: 91–98%) for patients with adiponectin levels in the 1st quartile, 87% (95% CI: 82–94%) for those in the 2nd quartile, 80% (95% CI: 73–88%) for the 3rd quartile, and 76% (95% CI: 69–84%) for the 4th quartile (Figure 3). Pairwise log-rank tests showed that the survival probability for patients with adiponectin levels in the 4th quartile was significantly lower than for those in the 1st (p < 0.001) and 2nd quartiles (p = 0.048), and for patients in the 3rd quartile compared to the 1st (p = 0.001).
Figure 3
Boxplot of baseline serum adiponectin levels (μg/mL) stratified by outcome status. The line within the box represents the median serum adiponectin levels, and each box represents the upper and lower quartiles. The jittered points around each boxplot represent the distribution of adiponectin. Statistical comparisons were made with Mann–Whitney U tests for two-group comparisons or Kruskal–Wallis tests in case of more than two independent samples, followed by Dunns’s post-hoc test for multiple comparisons. p, p-value.
Figure 4
Kaplan–Meier survival probability curves 90 days after admission according to sex-adjusted adiponectin quartiles for 502 patients with community-acquired pneumonia. The survival curves for the second, third and fourth quartiles were significantly different from the first quartile according to a log-rank test (p = 0.0031).
In minimally adjusted models, the odds ratio (OR) for 90-day mortality increased by 2% for each 1 μg/mL increase in adiponectin and was 199 and 234% higher for adiponectin levels in the 3rd and 4th quartiles, respectively, than in the 1st quartile (Table 4). When BMI was added to the analysis (the fully adjusted model), the association between adiponectin and 90-day mortality disappeared (Table 4). Likewise, the association disappeared when adjusted for waist circumference (n = 296) or body fat % (n = 311) (Table 5).
Table 4
| Outcomes | 90-day mortality | In-hospital mortality | 90-day readmission | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Minimally adjusted1 | Fully adjusted2 | Minimally adjusted1 | Fully adjusted2 | Minimally adjusted1 | Fully adjusted2 | |||||||||||||
| Predictors | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Adiponectin μg/ml | ||||||||||||||||||
| Continuous | 1.02 | 1.00–1.04 | 0.048 | 1.01 | 0.98–1.03 | 0.52 | 1.02 | 0.99–1.04 | 0.21 | 0.99 | 0.95–1.03 | 0.60 | 1.02 | 1.01–1.04 | 0.007 | 1.02 | 1.00–1.04 | 0.024 |
| 1st quartile | Ref. | Ref. | Ref. | Ref. | Ref. | |||||||||||||
| 2nd quartile | 1.96 | 0.79–5.19 | 0.15 | 1.87 | 0.68–5.54 | 0.23 | 3.65 | 0.85–25.05 | 0.11 | 3.66 | 0.84–25.40 | 0.12 | 1.25 | 0.71–2.20 | 0.44 | 1.15 | 0.63–2.11 | 0.64 |
| 3rd quartile | 2.99 | 1.29–7.59 | 0.014 | 1.57 | 0.59–4.52 | 0.38 | 5.82 | 1.47–38.37 | 0.025 | 2.38 | 0.52–16.84 | 0.30 | 1.87 | 1.07–3.27 | 0.028 | 1.47 | 0.79–2.75 | 0.23 |
| 4th quartile | 3.34 | 1.46–8.38 | 0.006 | 2.01 | 0.77–5.70 | 0.17 | 4.65 | 1.18–30.96 | 0.06 | 1.56 | 0.31–11.56 | 0.61 | 2.33 | 1.34–4.09 | 0.003 | 2.24 | 1.20–4.23 | 0.012 |
Logistic regression analyses of the association between adiponectin levels at admission and 90-day mortality, in-hospital mortality, and readmission.
Patients who died in the hospital were excluded from analyses where readmission was the outcome. BMI, body mass index; OR, odds ratio; CI, confidence interval; Ref., reference.
1Models were adjusted for age and sex.
2Models were adjusted for age, sex, and BMI.
3Adiponectin quartile ranges for females: <15 μg/mL, 15–21 μg/mL, 21.1–31 μg/mL, and >31 μg/mL for the first, second, third, and fourth quartile, respectively. The corresponding ranges for males: <12 μg/mL, 12–17 μg/mL, 17.1–26 μg/mL, and > 26 μg/mL for the first, second, third, and fourth quartile, respectively.
Table 5
| Outcome | 90-day mortality | |||||
|---|---|---|---|---|---|---|
| Fully adjusted1 (waist circumference, cm) |
Fully adjusted1 (body fat %) |
|||||
| Predictors | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Adiponectin μg/ml | ||||||
| Continuous | 1.01 | 0.98–1.04 | 0.67 | 1.02 | 0.99–1.04 | 0.24 |
| 21st quartile | Ref. | Ref. | ||||
| 2nd quartile | 1.23 | 0.36–4.29 | 0.74 | 1.56 | 0.46–5.75 | 0.48 |
| 3rd quartile | 1.31 | 0.41–4.42 | 0.65 | 1.44 | 0.44–5.16 | 0.55 |
| 4th quartile | 1.31 | 0.42–4.35 | 0.65 | 2.33 | 0.77–7.99 | 0.15 |
Logistic regression models of the association between adiponectin levels and 90-day mortality, adjusted for waist circumference or body fat %.
1Models were also adjusted for age and sex.
2Adiponectin quartile ranges for females: <15 μg/mL, 15–21 μg/mL, 21.1–31 μg/mL, and >31 μg/mL for the first, second, third, and fourth quartile, respectively. The corresponding ranges for males: <12 μg/mL, 12–17 μg/mL, 17.1–26 μg/mL, and > 26 μg/mL for the first, second, third, and fourth quartile, respectively. Ref., reference, OR, odds ratio; CI, confidence interval.
3.4 In-hospital mortality
Overall, 6.4% (n = 32) of the patients died in hospital. Their adiponectin levels were higher than those of patients who survived until discharge (Figure 5). The OR for in-hospital mortality was 482 and 365% higher for adiponectin levels in the 3rd and 4th quartiles, respectively, than in the 1st quartile in minimally adjusted models (Table 4). In the fully adjusted model, the association between adiponectin and in-hospital mortality disappeared (Table 4).
Figure 5
Boxplot of baseline serum adiponectin levels (μg/mL) stratified by in-hospital mortality. The line within the box represents the median serum adiponectin levels, and each box represents the upper and lower quartiles. The jittered points around each boxplot represent the distribution of adiponectin. Statistical comparisons were made with Mann–Whitney U tests for two-group comparisons. p, p-value.
3.5 ICU transferral, non-invasive respiratory support, length of stay and time to clinical stability
There were no associations between adiponectin levels and risk of ICU transferral, non-invasive respiratory support (Table 6), LOS or time to clinical stability in the minimally or fully adjusted models (Table 7).
Table 6
| Outcome | ICU admission | Non-invasive respiratory support | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Minimally adjusted1 | Fully adjusted2 | Minimally adjusted1 | Fully adjusted2 | |||||||||
| Predictors | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Adiponectin μg/ml | ||||||||||||
| Continuous | 1.00 | 0.96–1.04 | 0.80 | 0.99 | 0.93–1.03 | 0.59 | 1.01 | 0.98–1.03 | 0.52 | 1.00 | 0.97–1.03 | 0.97 |
| 31st quartile | Ref. | Ref. | ||||||||||
| 2nd quartile | 1.09 | 0.26–4.35 | 0.90 | 1.00 | 0.24–4.01 | 1.00 | 1.13 | 0.48–2.64 | 0.77 | 1.02 | 0.42–2.48 | 0.96 |
| 3rd quartile | 3.00 | 0.98–10.37 | 0.063 | 1.87 | 0.54–7.10 | 0.34 | 1.44 | 0.64–3.30 | 0.38 | 0.81 | 0.31–2.07 | 0.66 |
| 4th quartile | 0.94 | 0.18–4.22 | 0.94 | 0.59 | 0.08–3.15 | 0.56 | 1.31 | 0.56–3.07 | 0.53 | 1.06 | 0.42–2.71 | 0.90 |
Logistic regression models of the association between adiponectin levels, ICU admission and non-invasive respiratory support.
Patients with a do-not-resuscitate order or limitations on life-sustaining treatment were excluded from analyses where ICU admission was the outcome variable. OR, odds ratio; CI, confidence interval; Ref., reference.
1Models were adjusted for age and sex.
2Models were adjusted for age, sex, and BMI.
3Adiponectin quartile ranges for females: <15 μg/mL, 15–21 μg/mL, 21.1–31 μg/mL, and >31 μg/mL for the first, second, third, and fourth quartile, respectively. The corresponding ranges for males: <12 μg/mL, 12–17 μg/mL, 17.1–26 μg/mL, and >26 μg/mL for the first, second, third, and fourth quartile, respectively.
Table 7
| Outcomes | Length of stay | Time to clinical stability | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Minimally adjusted1 | Fully adjusted2 | Minimally adjusted1 | Fully adjusted2 | |||||||||
| Predictors | β | 95% CI | p-value | β | 95% CI | p-value | β | 95% CI | p-value | β | 95% CI | p-value |
| Adiponectin μg/ml | ||||||||||||
| Continuous | 1.00 | 0.99–1.00 | 0.20 | 0.99 | 0.99–1.00 | 0.11 | 0.99 | 0.98–1.00 | 0.055 | 0.99 | 0.98–1.00 | 0.152 |
| 31st quartile | Ref. | Ref. | Ref. | Ref. | ||||||||
| 2nd quartile | 0.97 | 0.78–1.20 | 0.75 | 0.93 | 0.73–1.19 | 0.58 | 0.89 | 0.66–1.21 | 0.47 | 0.88 | 0.64–1.22 | 0.44 |
| 3rd quartile | 0.90 | 0.72–1.13 | 0.36 | 0.84 | 0.65–1.08 | 0.17 | 0.88 | 0.64–1.19 | 0.40 | 0.80 | 0.57–1.12 | 0.20 |
| 4th quartile | 0.93 | 0.75–1.16 | 0.53 | 0.91 | 0.71–1.18 | 0.49 | 0.87 | 0.64–1.19 | 0.39 | 0.85 | 0.60–1.20 | 0.35 |
Linear regression models of the association between adiponectin levels and log-transformed length of stay and time to clinical stability.
Data are from linear regression analyses with the log-transformed length of stay and time to clinical stability as the dependent variables. Patients who died during admission were excluded from these analyses. Data are reported as fold change in regression coefficient (β) after back transformation. Ref., reference; CI, confidence interval.
1Models were adjusted for age and sex.
2Models were adjusted for age, sex, and BMI.
3Adiponectin quartile ranges for females: <15 μg/mL, 15–21 μg/mL, 21.1–31 μg/mL, and > 31 μg/mL for the first, second, third, and fourth quartile, respectively. The corresponding ranges for males: <12 μg/mL, 12–17 μg/mL, 17.1–26 μg/mL, and >26 μg/mL for the first, second, third, and fourth quartile, respectively.
3.6 90-day readmission
33.5% (n = 168) of the patients were readmitted within 90 days. Their adiponectin levels were higher than those of patients who were not readmitted (Figure 3). Exacerbation of chronic diseases and infections were the most common causes of readmission (Table 8). The OR for 90-day readmission increased by 2% for each μg/mL increase in adiponectin and was 87 and 133% higher for adiponectin levels in the 3rd and 4th quartiles, respectively, than the 1st quartile in minimally adjusted models. This association remained in the fully adjusted model when adiponectin was entered as a continuous variable and for adiponectin levels in the 4th quartile (Table 4). The results were similar when BMI was substituted for waist circumference or body fat % (Table 9).
Table 8
| Disease category | N (%) |
|---|---|
| 1Miscellaneous acute conditions | 67 (40) |
| 2Exacerbation of chronic disease | 52 (40) |
| 3Respiratory infection | 35 (21) |
| 4Other infections | 14 (8) |
Overall causes of readmission.
1Includes acute medical and surgical conditions (and not exacerbation of chronic diseases).
2For example, acute exacerbation or complication due to COPD, asthma, cancer, cardiovascular disease, neurological disease.
3For example, pneumonia, viral respiratory infection.
4For example, endocarditis, urinary tract infections, skin and soft-tissue infections.
Table 9
| Outcome | 90-day readmission | |||||
|---|---|---|---|---|---|---|
| Fully adjusted1 (Waist circumference, cm) |
Fully adjusted2 (Body fat %) |
|||||
| Predictors | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Adiponectin μg/ml | ||||||
| Continuous | 1.03 | 1.00–1.05 | 0.023 | 1.02 | 1.00–1.04 | 0.031 |
| 31st quartiles | Ref. | Ref. | ||||
| 2nd quartile | 1.22 | 0.59–2.50 | 0.589 | 0.97 | 0.50–1.89 | 0.936 |
| 3rd quartile | 1.71 | 0.83–3.57 | 0.147 | 1.31 | 0.67–2.57 | 0.427 |
| 4th quartile | 2.26 | 1.06–4.87 | 0.036 | 2.01 | 1.01–4.07 | 0.048 |
Logistic regression models of the association between adiponectin levels and 90-day readmission adjusted for waist circumference or body fat %.
Patients who died in hospital were excluded from these analyses. Ref., reference; OR, odds ratio; CI, confidence interval.
1Models were adjusted for age, sex, and waist circumference (cm).
2Models were adjusted for age, sex, and body fat %.
3Adiponectin quartile ranges for females: <15 μg/mL, 15–21 μg/mL, 21.1–31 μg/mL, and >31 μg/mL for the first, second, third, and fourth quartile, respectively. The corresponding ranges for males: <12 μg/mL, 12–17 μg/mL, 17.1–26 μg/mL, and >26 μg/mL for the first, second, third, and fourth quartile, respectively.
4 Discussion
Our study is the first to investigate whether adiponectin is associated with adverse clinical outcomes after hospitalization with CAP. We found a positive association between high adiponectin levels and 90-day mortality independent of age and sex in a dose–response-like relationship for adiponectin quartiles. The association disappeared in analyses adjusted for BMI and specific adiposity measurements such as waist circumference or fat percentage. Finally, high adiponectin levels were associated with an increased risk of 90-day readmission independent of age, sex, and adiposity.
In line with previous studies, we found that increasing age, female sex, presence of COPD and rheumatic disease, absence of diabetes mellitus, low CRP, and low BMI were independent predictors of higher adiponectin levels (9, 21, 28, 29), whereas the CURB-65 score was not. This finding suggests that disease severity does not independently affect adiponectin levels, supporting other studies in critically ill patients (21, 30, 31).
Our findings suggest that low body fat explained the association between high adiponectin levels and increased mortality risk.
Consistent with our findings, two studies of critically ill patients with sepsis demonstrated an association between high adiponectin levels and increased risk of 28-day and 30-day mortality in unadjusted analyses that disappeared in models adjusted for BMI (32, 33). In contrast, two other studies of critically ill patients with respiratory failure and sepsis found an association between high adiponectin levels and increased risk of 28-day and 60-day mortality independent of BMI (20, 21). In a study of patients with acute respiratory distress syndrome (ARDS), high adiponectin levels were associated with an increased risk of 60-day mortality independent of BMI only in a subgroup of patients with an extra-pulmonary cause of ARDS. However, there was no association in the entire cohort (34).
Compared to our study population, the patients in the cited studies were critically ill, younger, predominantly male, more ethnically diverse, more obese, and more frequently diagnosed with diabetes mellitus (20, 21, 32–34). Furthermore, none of the cited studies had body composition or waist circumference data and could, therefore, not assess adiponectin’s association with mortality accounting for the amount of adipose tissue or abdominal obesity. Another complicating factor is that the etiology of critical illness was heterogeneous across the cited studies, where only a minority were diagnosed with pneumonia (20, 21, 32–34). These differences in patient characteristics might explain why adiponectin was a predictor of mortality independent of BMI in some studies. As an outlier, a study showed that sepsis non-survivors had lower adiponectin levels than survivors (19). However, the authors did not include age, sex, or BMI in the adjusted analyses, a significant limitation of this study (19).
A limitation of using 90-day mortality as an outcome measure after CAP is that the proportion of deaths directly attributed to pneumonia decreases while the proportion of deaths secondary to underlying diseases increases over time (35). We found an association between adiponectin and in-hospital mortality in models adjusted for age and sex, suggesting that high adiponectin levels can predict mortality more likely directly attributed to CAP. However, the association was weak, with wide confidence intervals, indicating a small sample size.
Among the patients who survived until discharge, we found no association between adiponectin levels and adverse clinical outcomes during hospitalization. Therefore, our results suggest that adiponectin is not associated with a more severe or protracted course of CAP. Our findings are supported by a small study of critically ill patients with SARS-CoV2 and non-SARS-CoV2 pneumonia that found no association between adiponectin levels and duration of mechanical ventilation (31).
Our study is the first to show that high adiponectin levels are associated with an increased risk of readmission after an acute hospitalization for CAP. Furthermore, the association was independent of adiposity. Readmission after CAP is often due to worsening pre-existing diseases, as shown by our data and others (36). In line with our results, a study of patients with heart failure showed an increased risk of mortality and readmission independent of BMI with increasing adiponectin levels (37). However, a limitation of this study was the use of mortality and readmission as a composite outcome (37). Adiponectin resistance may explain why high adiponectin levels are associated with worse outcomes in heart failure (18, 38). These considerations could be relevant to our findings. Future studies should investigate whether adiponectin can predict specific causes of readmissions after CAP. Our findings suggest that high adiponectin levels in hospitalized patients with CAP may reflect the negative influence of aging and comorbidities on body composition, specifically low body fat mass. Therefore, we speculate that high adiponectin may be a biomarker of adverse body composition associated with mortality and readmission in patients with CAP. However, our findings need to be replicated and validated in different settings.
4.1 Strengths and limitations
The prospective design, standardized data collection and detailed characterization of body composition are strengths of our study. Furthermore, we consider our cohort representative of patients hospitalized with CAP in a high-income, European country since we only had one exclusion criterion.
Nevertheless, our single-center study design limits the generalisability of the results. In addition, we cannot rule out consent bias since the study participants had to give active consent, thus excluding incapacitated patients. Another study limitation was the lack of a BMI measurement in 20% of patients. The patients without a BMI measurement had more severe CAP and thus could not fully participate in the study. Even though patients without a BMI had a higher mortality rate than those with a BMI, we do not expect this to have affected the overall associations because adiponectin levels were similar in both groups but increased the chances of type II error.
5 Conclusion
In conclusion, adiponectin was a predictor of mortality and readmission. The association with mortality depended on low body fat, whereas the association with readmission risk was independent of adiposity.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, upon reasonable request.
Ethics statement
The studies involving humans were approved by Scientific Ethics Committee at the Capital Region of Denmark. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
AD: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Visualization, Writing – original draft, Writing – review & editing. CR: Data curation, Writing – review & editing. MH: Data curation, Writing – review & editing. AS: Data curation, Writing – review & editing. AJ: Writing – review & editing. PK: Writing – review & editing. RK-M: Conceptualization, Methodology, Supervision, Writing – review & editing. DF-J: Conceptualization, Methodology, Supervision, Writing – review & editing. BL: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the Research Council at Copenhagen University Hospital, North Zealand, Grosserer L. F. Foghts Fond, Olga Bryde Nielsens Fond, Helen Rudes Fond, Kaptajnløjtnant Harald Jensens og Hustrus Fond, and Fonden til Lægevidenskabens Fremme. The funding sources were not involved in the study design, data collection, data analysis, interpretation of data, writing of the manuscript, or decision to submit the manuscript for publication.
Acknowledgments
We acknowledge the research nurses Hanne Hallager, Malene Pilegaard Schønnemann, and Christina Brix (Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, North Zealand, Denmark) for their assistance with enrolment of study participants and data collection. Lene Foged (Centre for Physical Activity Research, Copenhagen University Hospital, Rigshospitalet) is acknowledged for performing the analysis of adiponectin.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024.1329417/full#supplementary-material
References
1.
GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. (2020) 396:1204–22. doi: 10.1016/S0140-6736(20)30925-9
2.
Kornum JB Thomsen RW Riis A Lervang HH Schønheyder HC Sørensen HT . Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care. (2007) 30:2251–7. doi: 10.2337/dc06-2417
3.
Jensen AV Baunbæk Egelund G Bang Andersen S Petersen PT Benfield T Witzenrath M et al . The Glycemic gap and 90-day mortality in community-acquired pneumonia. A prospective cohort study. Ann Am Thorac Soc. (2019) 16:1518–26. doi: 10.1513/AnnalsATS.201901-007OC
4.
Andersen SB Baunbæk Egelund G Jensen AV Petersen PT Rohde G Ravn P . Failure of CRP decline within three days of hospitalization is associated with poor prognosis of community-acquired pneumonia. Infect Dis. (2017) 49:251–60. doi: 10.1080/23744235.2016.1253860
5.
Torres A Peetermans WE Viegi G Blasi F . Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. (2013) 68:1057–65. doi: 10.1136/thoraxjnl-2013-204282
6.
Kornum JB Nørgaard M Dethlefsen C Due KM Thomsen RW Tjønneland A et al . Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J. (2010) 36:1330–6. doi: 10.1183/09031936.00184209
7.
Kim RY Glick C Furmanek S Ramirez JA Cavallazzi R . Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. ERJ Open Res. (2021) 7:00736–2020. doi: 10.1183/23120541.00736-2020
8.
Achamrah N Colange G Delay J Rimbert A Folope V Petit A et al . Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures. PLoS One. (2018) 13:e0200465. doi: 10.1371/journal.pone.0200465
9.
Obata Y Yamada Y Takahi Y Baden MY Saisho K Tamba S et al . Relationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetes. Clin Endocrinol. (2013) 79:204–10. doi: 10.1111/cen.12041
10.
Ouchi N Kihara S Funahashi T Nakamura T Nishida M Kumada M et al . Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. (2003) 107:671–4. doi: 10.1161/01.CIR.0000055188.83694.B3
11.
Wang Y Ma XL Lau WB . Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metab. (2017) 28:519–30. doi: 10.1016/j.tem.2017.03.004
12.
Reneau J Goldblatt M Gould J Kindel T Kastenmeier A Higgins R et al . Effect of adiposity on tissue-specific adiponectin secretion. PLoS One. (2018) 13:e0198889. doi: 10.1371/journal.pone.0198889
13.
Woelnerhanssen B Peterli R Steinert RE Peters T Borbély Y Beglinger C . Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis. (2011) 7:561–8. doi: 10.1016/j.soard.2011.01.044
14.
Villareal DT Fontana L Das SK Redman L Smith SR Saltzman E et al . Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. J Bone Miner Res. (2016) 31:40–51. doi: 10.1002/jbmr.2701
15.
Szabó T Scherbakov N Sandek A Kung T von Haehling S Lainscak M et al . Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. (2014) 24:50–6. doi: 10.1016/j.numecd.2013.04.015
16.
Mokari-Yamchi A Sharifi A Kheirouri S . Increased serum levels of S100A1, ZAG, and adiponectin in cachectic patients with COPD. Int J Chron Obstruct Pulmon Dis. (2018) 13:3157–63. doi: 10.2147/COPD.S172996
17.
Mannelli M Gamberi T Magherini F Fiaschi T . The adipokines in cancer cachexia. Int J Mol Sci. (2020) 21:4860. doi: 10.3390/ijms21144860
18.
Menzaghi C Trischitta V . The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. (2018) 67:12–22. doi: 10.2337/dbi17-0016
19.
Wang H Gao YX Wu YN Li C Duan J . Association between plasma adiponectin levels and left ventricular systolic dysfunction in sepsis patients. J Crit Care. (2020) 60:195–201. doi: 10.1016/j.jcrc.2020.06.020
20.
Koch A Sanson E Voigt S Helm A Trautwein C Tacke F . Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care. (2011) 26:166–74. doi: 10.1016/j.jcrc.2010.07.015
21.
Walkey AJ Rice TW Konter J Ouchi N Shibata R Walsh K et al . Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care Med. (2010) 38:2329–34. doi: 10.1097/CCM.0b013e3181fa0561
22.
von Elm E Altman DG Egger M Pocock SJ Gøtzsche PC Vandenbroucke JP et al . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X
23.
World Medical Association Declaration of Helsinki . Ethical principles for medical research involving human subjects. Bull World Health Organ. (2001) 79:373–4.
24.
Harris PA Taylor R Minor BL Elliott V Fernandez M O'Neal L et al . The REDCap consortium: building an international community of software platform partners. J Biomed Inform. (2019) 95:103208. doi: 10.1016/j.jbi.2019.103208
25.
Capelastegui A España PP Quintana JM Areitio I Gorordo I Egurrola M et al . Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. (2006) 27:151–7. doi: 10.1183/09031936.06.00062505
26.
Menéndez R Martinez R Reyes S Mensa J Polverino E Filella X et al . Stability in community-acquired pneumonia: one step forward with markers?Thorax. (2009) 64:987–92. doi: 10.1136/thx.2009.118612
27.
Baker JF Newman AB Kanaya A Leonard MB Zemel B Miljkovic I et al . The adiponectin paradox in the elderly: associations with body composition, physical functioning, and mortality. J Gerontol A Biol Sci Med Sci. (2019) 74:247–53. doi: 10.1093/gerona/gly017
28.
Carolan BJ Kim Y Williams AA Kechris K Lutz S Reisdorph N et al . The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2013) 188:561–6. doi: 10.1164/rccm.201212-2299OC
29.
Meyer M Sellam J Fellahi S Kotti S Bastard JP Meyer O et al . Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. (2013) 15:R210. doi: 10.1186/ar4404
30.
Vassiliadi DA Tzanela M Kotanidou A Orfanos SE Nikitas N Armaganidis A et al . Serial changes in adiponectin and resistin in critically ill patients with sepsis: associations with sepsis phase, severity, and circulating cytokine levels. J Crit Care. (2012) 27:400–9. doi: 10.1016/j.jcrc.2012.04.007
31.
Blot M Masson D Nguyen M Bourredjem A LYMPHONIE Study Group Andreu P et al . Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19?Int J Obes. (2021) 45:2126–31. doi: 10.1038/s41366-021-00868-5
32.
Karampela I Kandri E Antonakos G Vogiatzakis E Christodoulatos GS Nikolaidou A et al . Kinetics of circulating fetuin-a may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: a prospective study. J Crit Care. (2017) 41:78–85. doi: 10.1016/j.jcrc.2017.05.004
33.
Palakshappa JA Anderson BJ Reilly JP Shashaty MGS Ueno R Wu Q et al . Low plasma levels of adiponectin do not explain acute respiratory distress syndrome risk: a prospective cohort study of patients with severe sepsis. Crit Care. (2016) 20:71. doi: 10.1186/s13054-016-1244-2
34.
Walkey AJ Demissie S Shah D Romero F Puklin L Summer RS . Plasma adiponectin, clinical factors, and patient outcomes during the acute respiratory distress syndrome. PLoS One. (2014) 9:e108561. doi: 10.1371/journal.pone.0108561
35.
Mortensen EM Coley CM Singer DE Marrie TJ Obrosky DS Kapoor WN et al . Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study. Arch Intern Med. (2002) 162:1059–64. doi: 10.1001/archinte.162.9.1059
36.
Boussat B Cazzorla F Le Marechal M Pavese P Mounayar AL Sellier E et al . Incidence of avoidable 30-day readmissions following hospitalization for community-acquired pneumonia in France. JAMA Netw Open. (2022) 5:e226574. doi: 10.1001/jamanetworkopen.2022.6574
37.
Van Berendoncks AM Beckers P Hoymans VY Possemiers N Coenen S Elseviers MM et al . β-Blockers modify the prognostic value of adiponectin in chronic heart failure. Int J Cardiol. (2011) 150:296–300. doi: 10.1016/j.ijcard.2010.04.039
38.
Van Berendoncks AM Garnier A Beckers P Hoymans VY Possemiers N Fortin D et al . Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart. (2011) 97:1403–9. doi: 10.1136/hrt.2011.226373
Summary
Keywords
community-acquired pneumonia, adiponectin, body mass index, mortality, readmission
Citation
Dungu AM, Ryrsø CK, Hegelund MH, Sejdic A, Jensen AV, Kristensen PL, Krogh-Madsen R, Faurholt-Jepsen D and Lindegaard B (2024) Adiponectin as a predictor of mortality and readmission in patients with community-acquired pneumonia: a prospective cohort study. Front. Med. 11:1329417. doi: 10.3389/fmed.2024.1329417
Received
20 November 2023
Accepted
11 March 2024
Published
02 April 2024
Volume
11 - 2024
Edited by
Akio Shimizu, The University of Nagano, Japan
Reviewed by
Geovane Rossone Reis, UnirG, Brazil
Yuria Ishida, Aichi Medical University, Japan
Updates
Copyright
© 2024 Dungu, Ryrsø, Hegelund, Sejdic, Jensen, Kristensen, Krogh-Madsen, Faurholt-Jepsen and Lindegaard.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Arnold Matovu Dungu, Arnold.matovu.dungu@regionh.dk
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.